The global health community is ramping up efforts to combat a threatening outbreak of Ebola, with three promising vaccines currently under development. The International Aids Vaccine Initiative (IAVI), in collaboration with Moderna and the University of Oxford, is racing against time to deliver solutions amid fears that this outbreak could escalate to unprecedented levels.
As the International Aids Vaccine Initiative warns of the outbreak potentially becoming the worst in history, nearly 1,000 suspected cases have been reported in the Democratic Republic of the Congo (DRC), alongside confirmed cases in Uganda. The current death toll has surged to nearly 250, raising alarms reminiscent of the devastating 2014-2016 West Africa outbreak, which infected an estimated 29,000 individuals.
Calls for Urgency Amid Alarming Growth
Dr. Mark Feinberg, head of IAVI, noted the urgency as he declared, "This situation is clearly threatening to become as severe, if not worse, than past outbreaks. The development of a vaccine and related countermeasures is an urgent priority." His sentiment echoes that of Médecins Sans Frontières (MSF), which has called the situation "deeply alarming" with record case numbers occurring at an unprecedented pace.
Understanding the Bundibugyo Outbreak
The current outbreak stems from the Bundibugyo species of the virus, a strain that has only been documented twice before, notably lacking an approved vaccine to date. There have been effective vaccines developed for the more common Zaire species, but the development of tailored vaccines for each virus type is essential for containment.
IAVI is focusing on a modified version of the Zaire Ebola vaccine, recently tested in primates where it demonstrated an almost 100% efficiency in inducing an immune response. Dr. Feinberg stated, "While we remain optimistic based on preliminary evidence, preparing the vaccine for clinical trials could take seven to nine months, though we are working to accelerate this timeline."
Innovative Technologies Explored
In parallel, Moderna has adapted its mRNA technology, originally utilized in rapid COVID-19 vaccine development, to create a candidate for the Bundibugyo virus. CEO Stéphane Bancel emphasized their commitment: "We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most." Similarly, the University of Oxford is leveraging its successes in COVID-19 vaccine technology to forge a novel response against Ebola, voicing readiness for clinical trials within months.
Each vaccine aims to harness the body’s immune response by targeting the Bundibugyo glycoprotein found on the viral surface. IAVI utilizes a genetically engineered, non-harmful virus to elicit a defensive reaction, while both Moderna and Oxford’s candidates introduce genetic material to instruct cells to construct the viral protein for immune recognition.
Global Health Leaders Rally for Action
Dr. Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI), underscored the urgency of the situation, stating, "With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease." Public health authorities, including Dr. Tedros Adhanom Ghebreyesus of the World Health Organization, have reiterated that a Bundibugyo vaccine could be a pivotal element in controlling the current outbreak and fortifying defenses against future diseases.
As efforts intensify, the world watches closely, awaiting breakthroughs that may hold the key to quelling this potential outbreak before it escalates further.
Source: BBC News
Source: BBC News - Health